摘要
脓毒症(sepsis)是宿主对感染的反应失调,并产生危及生命的器官功能障碍,常发生在烧伤、感染、多发伤等临床急危重疾病的基础上,也是导致多器官功能障碍综合征(MODS)的重要原因之一,病情凶险,临床病死率高。脓毒症诱导的心肌抑制(sepsis-induced myocardial dysfunction,SIMD)是严重脓毒症和脓毒性休克常见的并发症之一,是导致脓毒症多器官功能障碍及其病死率增加的重要因素。一种新型钙增敏剂——左西孟旦,在失代偿性心衰治疗中发挥了较好的疗效,目前在脓毒症中也得到一定的应用,但是存在一定的争议。近年来对左西孟旦在脓毒症中的作用,国内外进行多项临床试验,现就其在脓毒症中的作用进展作一综述。
Sepsis is the response disorder of the host to infection, which produces life-threatening organ dysfunction and often occurs on the basis of clinical acute and critical diseases including burns, infections, multiple injuries, and is one of the important reasons leading to multiple organ dysfunction syndrome（MODS）. The disease is dangerous and has high clinical mortality. Sepsis-induced myocardial dysfunction（SIMD） is one of the most common complications of se- vere sepsis and septic shock, which is an important factor leading to the increase of multiple organ dysfunction and the mortality of sepsis. A new calcium sensitizer levosimendan plays a very good effect in the treatment of decompen- sated heart failure, and also has a certain application in sepsis. But there is a certain controversy. In recent years, a number of clinical trials at home and abroad on the role of levosimendan in sepsis have been carried out. The progress of the role of levosimendan in the treatment of sepsis will be reviewed in this paper.
出处
《中国现代医生》
2017年第36期161-164,168,共5页
China Modern Doctor
基金
浙江省医药卫生科技计划项目(骨干人才A类)(2016RCA014)
浙江省医药卫生科研基金项目(2017KY371)
